ERBB2 and depressive symptom measurement: As expected, individuals in the combination groups were younger, healthier (except for a higher prevalence of depression/anxiety), had more advanced tumor stage, more often HER2-positive disease, and received more extensive treatment than individuals in the single treatment groups.